Policy of funding growth investments with internal funds
First written in FY2016. 5 of 12 entries say "Advanced", first in FY2018. Latest entry: FY2026.
5 other companies' latest entry also says "Raised".
- FY2026RaisedAnnual report
「The company and consolidated subsidiaries: research and development facilities, 58,000, April 2025, March 2028 / the company and consolidated subsidiaries: production facilities such as molds, 5,000, April 2025, March 2028 / the company: technology development building, 121,000, December 2025, March 2029 / the company and consolidated subsidiaries: renovation and renewal of buildings and other assets, 46,000, April 2025, March 2028 / total, 230,000」
The capital investment plan was expanded to a total of ¥230 billion through March 2029, including a new ¥121 billion technology development building. The required funding is planned to be provided from internal funds. - 2026-05-08RestatedRevisions to earnings forecasts
「当社は、会社の成長に必要な研究開発や設備投資等を内部留保資金でまかなうことを原則とし、将来の経営環境の変化への対応や、厳しい競争に勝ち抜くため、財務面での健全性を維持しつつ、株主の皆様への直接的な利益還元については、各期の利益水準を勘案した配当により実施することを基本方針としています。」
研究開発・設備投資等を内部留保資金で賄う原則と、財務健全性を維持しながら利益水準を勘案して配当する方針を再確認している。 - FY2025RaisedAnnual report
「The company and consolidated subsidiaries: research and development facilities, 58,000, April 2024, March 2027 / the company and consolidated subsidiaries: production facilities such as molds, 6,000, April 2024, March 2027 / the company and consolidated subsidiaries: renovation and renewal of buildings and other assets, 94,000, April 2024, March 2027 / total, 158,000」
The total capital investment plan scheduled for completion in March 2027 was expanded to ¥158 billion, covering the renovation and renewal of research and development facilities, production facilities, buildings and other assets. Future required funding is planned to be provided from internal funds. - FY2024RaisedAnnual report
「The company and consolidated subsidiaries: research and development facilities, 42,000, April 2023, March 2026 / the company and consolidated subsidiaries: production facilities such as molds, 7,000, April 2023, March 2026 / the company and consolidated subsidiaries: renovation and renewal of buildings and other assets, 66,000, April 2023, March 2026 / total, 115,000」
The total capital investment plan scheduled for completion in March 2026 was set at ¥115 billion, covering research and development facilities, production facilities such as molds, and the renovation and renewal of buildings and other assets. The required funding is planned to be provided from internal funds. - FY2023AdvancedAnnual report
「During the consolidated fiscal year, we made capital expenditures of ¥33.933 billion. These expenditures were primarily related to research and development facilities and included intangible fixed assets such as software for internal use. All required funding for the capital expenditures was provided from internal funds, and no external financing was undertaken.」
The company funded the full ¥33.933 billion of capital investment in research and development facilities and other assets with internal funds. It also plans to fund with internal funds the total ¥84 billion capital investment program scheduled for completion in March 2025. - FY2022RestatedAnnual report
「During the consolidated fiscal year, we made capital expenditures of ¥16.766 billion. These expenditures were primarily related to research and development facilities and included intangible fixed assets such as software for internal use. All required funding for the capital expenditures was provided from internal funds, and no external financing was undertaken.」
The company continued capital investment in research and development facilities and other assets, funding the full ¥16.766 billion invested during the fiscal year with internal funds. - FY2021AdvancedAnnual report
「During the consolidated fiscal year, we made capital expenditures of ¥17.912 billion. These expenditures were primarily related to research and development facilities and included intangible fixed assets such as software for internal use. All required funding for the capital expenditures was provided from internal funds, and no external financing was undertaken.」
The company funded the full ¥1.7912 trillion of capital expenditure with internal funds and indicated plans to fund with internal funds the future required funding for the total ¥49 billion capital investment program scheduled for completion in March 2023. - FY2020AdvancedAnnual report
「During the consolidated fiscal year, we made capital expenditures of ¥17.077 billion. These expenditures were primarily related to research and development facilities and included intangible fixed assets such as software for internal use. All required funding for the capital expenditures was provided from internal funds, and no external financing was undertaken.」
The company funded the full ¥17.077 billion of capital expenditure during the fiscal year with internal funds. It also plans to fund with internal funds the ¥24.923 billion of future required funding for the total ¥42 billion capital investment program scheduled for completion in March 2022. - FY2019AdvancedAnnual report
「During the consolidated fiscal year, we made capital expenditures of ¥16.093 billion. These expenditures were primarily related to research and development facilities and included intangible fixed assets such as software for internal use. All required funding for the capital expenditures was provided from internal funds, and no external financing was undertaken.」
The company funded the full ¥16.093 billion of capital expenditure during the fiscal year with internal funds. It also plans to fund with internal funds the ¥23.907 billion of future required funding for the total ¥40 billion capital investment program scheduled for completion in March 2021. - FY2018AdvancedAnnual report
「During the consolidated fiscal year, we made capital expenditures of ¥13.082 billion. These expenditures were primarily related to research and development facilities and included intangible fixed assets such as software for internal use. All required funding for the capital expenditures was provided from internal funds, and no external financing was undertaken.」
The company funded the full ¥13.082 billion of capital expenditure during the fiscal year with internal funds. In addition, it plans to fund with internal funds the total ¥39 billion capital investment program scheduled for completion in March 2020, including research and development facilities. - FY2017RestatedAnnual report
「As a general principle, we fund the research and development, capital expenditure and other activities required for the company’s growth with retained earnings.」
The company reaffirmed its policy of funding research and development, capital expenditure and other investments from retained earnings, and funded ¥15.158 billion of capital expenditure during the fiscal year with internal funds. - FY2016First statedAnnual report
「As a general principle, we fund the research and development, capital expenditure and other activities required for the company’s growth with retained earnings.」
Policy of funding research and development, capital expenditure, production capacity, raw materials, advertising and promotional activities, network infrastructure and other investments from retained earnings.